Ann: Bods exclusive partner iX Biopharma secures China patent, page-5

This timeously coincides with the Australian Governments plans to legalise the export of medicinal cannabis products, subject to federal approval in February and leaves Bod Australia incredibly well positioned to leverage an untapped and expanding medicinal cannabis market which is estimated to reach US$55.8 billion by 2025.1
Further, the Company has made significant progress in the commencement of its Phase I Clinical Trials. Most recently contracts have been finalised with all clinical trial vendors, a Clinical Research Organisation (CRO) has been chosen to coordinate the trial, patient recruitment is being finalised through the Company’s chosen Phase I trial centre in Victoria and data management, medicinal management and bio analysis procedures have all been finalised.
As well, the Company will be hosting its inaugural Advisory Board meeting this month involving key physicians and scientists which will include discussion on trial design and the investigation of additional collaborations for future trial developments and opportunities. (my emphasis)​

Tackling multiple prerequisites to successful commercialization, happy to hold this one.